Success Metrics

Clinical Success Rate
100.0%

Based on 1 completed trials

Completion Rate
100%(1/1)
Active Trials
1(25%)
Results Posted
0%(0 trials)

Phase Distribution

Ph not_applicable
1
25%
Ph phase_1
2
50%
Ph phase_2
1
25%

Phase Distribution

2

Early Stage

1

Mid Stage

0

Late Stage

Phase Distribution4 total trials
Phase 1Safety & dosage
2(50.0%)
Phase 2Efficacy & side effects
1(25.0%)
N/ANon-phased studies
1(25.0%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

100.0%

1 of 1 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

1

trials recruiting

Total Trials

4

all time

Status Distribution
Active(1)
Completed(1)
Other(2)

Detailed Status

unknown2
Completed1
Recruiting1

Development Timeline

Analytics

Development Status

Total Trials
4
Active
1
Success Rate
100.0%
Most Advanced
Phase 2

Trials by Phase

Phase 12 (50.0%)
Phase 21 (25.0%)
N/A1 (25.0%)

Trials by Status

completed125%
recruiting125%
unknown250%

Recent Activity

1 active trials
Showing 4 of 4
recruitingnot_applicable

CIK Cell Therapy for Relapsed or Refractory Acute B-Lymphoblastic Leukemia: Prognostic Impact on Patients With Early CAR-T Cell Dysfunction

NCT06389305
unknownphase_1

Study of Autologous CIK Cell Immunotherapy Combination With PD-1 Inhibitor and Chemotherapy in the Advanced NSCLC

NCT03987867
completedphase_2

Study of Chemotherapy Combination With Autologous Cytokine-Induced Killer Cell Immunotherapy to Treat Lung Cancer

NCT01631357
unknownphase_1

A Study to Evaluate Autologous CIK Cells in Patients With Hepatocellular Carcinoma After TACE, PEIT or RFA

NCT03124498

Clinical Trials (4)

Showing 4 of 4 trials
NCT06389305Not Applicable

CIK Cell Therapy for Relapsed or Refractory Acute B-Lymphoblastic Leukemia: Prognostic Impact on Patients With Early CAR-T Cell Dysfunction

Recruiting
NCT03987867Phase 1

Study of Autologous CIK Cell Immunotherapy Combination With PD-1 Inhibitor and Chemotherapy in the Advanced NSCLC

Unknown
NCT01631357Phase 2

Study of Chemotherapy Combination With Autologous Cytokine-Induced Killer Cell Immunotherapy to Treat Lung Cancer

Completed
NCT03124498Phase 1

A Study to Evaluate Autologous CIK Cells in Patients With Hepatocellular Carcinoma After TACE, PEIT or RFA

Unknown

All 4 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
4